11916 related articles for article (PubMed ID: 1371427)
21. Synergistic effects of phorbol ester and interferon-alpha: target cell class I HLA antigen expression and resistance to natural killer and lymphokine-activated killer cell-mediated cytolysis.
Migita K; Eguchi K; Akiguchi I; Ida H; Kawakami A; Ueki Y; Kurata A; Fukuda T; Nagataki S
Cell Immunol; 1991 May; 134(2):325-35. PubMed ID: 2021973
[TBL] [Abstract][Full Text] [Related]
22. Bovine NK and LAK susceptibility is independent of class I expression on B lymphoblastoid variants.
Li W; Splitter GA
Vet Immunol Immunopathol; 1994 Jun; 41(3-4):189-200. PubMed ID: 7941303
[TBL] [Abstract][Full Text] [Related]
23. The murine nonclassical class I major histocompatibility complex-like CD1.1 molecule protects target cells from lymphokine-activated killer cell cytolysis.
Chang CS; Brossay L; Kronenberg M; Kane KP
J Exp Med; 1999 Feb; 189(3):483-91. PubMed ID: 9927510
[TBL] [Abstract][Full Text] [Related]
24. Relation of natural killer cell line NK-92-mediated cytolysis (NK-92-lysis) with the surface markers of major histocompatibility complex class I antigens, adhesion molecules, and Fas of target cells.
Komatsu F; Kajiwara M
Oncol Res; 1998; 10(10):483-9. PubMed ID: 10338151
[TBL] [Abstract][Full Text] [Related]
25. Role of LFA-3, ICAM-1, and MHC class I on the sensitivity of human tumor cells to LAK cells.
Gwin JL; Gercel-Taylor C; Taylor DD; Eisenberg B
J Surg Res; 1996 Jan; 60(1):129-36. PubMed ID: 8592403
[TBL] [Abstract][Full Text] [Related]
26. Cytokine modulation of antigen expression in human melanoma cell lines derived from primary and metastatic tumour tissues.
Andalib AR; Lawry J; Ali SA; Murray AK; Sisley K; Silcocks P; Herlyn M; Rees RC
Melanoma Res; 1997 Feb; 7(1):32-42. PubMed ID: 9067963
[TBL] [Abstract][Full Text] [Related]
27. Recombinant gamma interferon provokes resistance of human breast cancer cells to spontaneous and IL-2 activated non-MHC restricted cytotoxicity.
Jabrane-Ferrat N; Calvo F; Faille A; Lagabrielle JF; Boisson N; Quillet A; Fradelizi D
Br J Cancer; 1990 Apr; 61(4):558-62. PubMed ID: 2109997
[TBL] [Abstract][Full Text] [Related]
28. Increased susceptibility of IFN-gamma-treated neuroblastoma cells to lysis by lymphokine-activated killer cells: participation of ICAM-1 induction on target cells.
Naganuma H; Kiessling R; Patarroyo M; Hansson M; Handgretinger R; Grönberg A
Int J Cancer; 1991 Feb; 47(4):527-32. PubMed ID: 1671670
[TBL] [Abstract][Full Text] [Related]
29. Target lysis by human LAK cells is critically dependent upon target binding properties, but LFA-1, LFA-3 and ICAM-1 are not the major adhesion ligands on targets.
Quillet-Mary A; Cavarec L; Kermarrec N; Marchiol-Fournigault C; Gil ML; Conjeaud H; Fradelizi D
Int J Cancer; 1991 Feb; 47(3):473-9. PubMed ID: 1704356
[TBL] [Abstract][Full Text] [Related]
30. The effect of bryostatin 1 on human lymphocyte-mediated cytotoxicity.
Tilden AB; Kraft AS
J Immunother (1991); 1991 Apr; 10(2):96-104. PubMed ID: 1828367
[TBL] [Abstract][Full Text] [Related]
31. Distinct characteristics of lymphokine-activated killer (LAK) cells derived from patients with B-cell chronic lymphocytic leukemia (B-CLL). A factor in B-CLL serum promotes natural killer cell-like LAK cell growth.
Santiago-Schwarz F; Panagiotopoulos C; Sawitsky A; Rai KR
Blood; 1990 Oct; 76(7):1355-60. PubMed ID: 2207313
[TBL] [Abstract][Full Text] [Related]
32. Pentoxifylline-induced modulation of melanoma cell growth, adhesion and lymphokine activated killer cell-mediated lysis.
Alexander CL; Edward M; MacKie RM
Melanoma Res; 1999 Feb; 9(1):31-9. PubMed ID: 10338332
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of lymphokine-activated killer cell-mediated cytotoxicity by phorbol ester.
Nishimura T; Burakoff SJ; Herrmann SH
J Immunol; 1989 Mar; 142(6):2155-61. PubMed ID: 2646377
[TBL] [Abstract][Full Text] [Related]
34. Interaction of natural killer cells with MHC class II: reversal of HLA-DR1-mediated protection of K562 transfectant from natural killer cell-mediated cytolysis by brefeldin-A.
Jiang YZ; Couriel D; Mavroudis DA; Lewalle P; Malkovska V; Hensel NF; Dermime S; Molldrem J; Barrett AJ
Immunology; 1996 Mar; 87(3):481-6. PubMed ID: 8778037
[TBL] [Abstract][Full Text] [Related]
35. The relationship between multi-drug resistance and resistance to natural-killer-cell and lymphokine-activated killer-cell lysis in human leukemic cell lines.
Treichel RS; Olken S
Int J Cancer; 1992 Jan; 50(2):305-10. PubMed ID: 1370437
[TBL] [Abstract][Full Text] [Related]
36. Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104.
Brando C; Mukhopadhyay S; Kovacs E; Medina R; Patel P; Catina TL; Campbell KS; Santoli D
J Leukoc Biol; 2005 Aug; 78(2):359-71. PubMed ID: 15937142
[TBL] [Abstract][Full Text] [Related]
37. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
Colquhoun SD; Economou JS; Shau H; Golub SH
J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
[TBL] [Abstract][Full Text] [Related]
38. Cytokine regulation of cell-to-cell interactions in lymphokine-activated killer cell cytotoxicity in vitro.
Takahashi T; Ishikura H; Iwai K; Takahashi C; Kato H; Tanabe T; Yoshiki T
Cancer Immunol Immunother; 1993; 36(2):76-82. PubMed ID: 8093857
[TBL] [Abstract][Full Text] [Related]
39. Expression of the adhesion molecules ICAM-1 and ICAM-2 on tumor cell lines does not correlate with their susceptibility to natural killer cell-mediated cytolysis: evidence for additional ligands for effector cell beta integrins.
Akella R; Hall RE
Eur J Immunol; 1992 Apr; 22(4):1069-74. PubMed ID: 1348028
[TBL] [Abstract][Full Text] [Related]
40. Human natural killer cell adhesion molecules. Differential expression after activation and participation in cytolysis.
Robertson MJ; Caligiuri MA; Manley TJ; Levine H; Ritz J
J Immunol; 1990 Nov; 145(10):3194-201. PubMed ID: 1700001
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]